Surrozen Inc Dossier
Qualitative Analysis
Business overview
Surrozen Inc. (Nasdaq: SRZN) is a clinical-stage biotechnology company pioneering targeted therapeutics designed to selectively modulate the Wnt pathway, a critical mediator of tissue repair and regeneration. The company's primary strategic focus is on ophthalmology, leveraging its deep Wnt biology expertise and proprietary antibody-engineering platforms to develop multifunctional biologics that address severe, sight-threatening retinal vascular-associated diseases. Surrozen's pipeline includes SZN-8141, a bi-functional candidate combining Frizzled 4 (Fzd4) agonism and vascular endothelial growth factor (VEGF) antagonism, and SZN-413, a Fzd4-targeted bi-specific antibody being developed in collaboration with Boehringer Ingelheim.
Research as of 24 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Surrozen strategically pivoted to focus its Wnt biology expertise and antibody technologies entirely on ophthalmology programs, specifically targeting retinopathies, after discontinuing the development of its liver drug candidate SZN-043.
Expected impact: Aims to advance lead candidates SZN-8141 and SZN-8143 through initial Phase 1 safety, tolerability, and efficacy studies in severe eye diseases like wet AMD and diabetic macular edema.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides external validation of Surrozen's SWAP technology platform and non-dilutive funding to support the development of SZN-413 for retinal vascular diseases.
Terms: $12.5 million upfront payment, with eligibility to receive up to $586.5 million in success-based development, regulatory, and commercial milestones, plus mid-single to low-double digit royalties on sales.